Related Experiment Video
Updated: Jun 7, 2025
12:45
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
5.6K
Oncological Outcomes Following Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer:
Alireza Ghoreifi1, Farshad Sheybaee Moghaddam1, Anirban P Mitra2
1Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
European Urology Focus
|November 17, 2024
Summary
Robotic postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) shows promising oncological outcomes for testicular cancer patients. This minimally invasive approach offers acceptable cancer control with a 4-year recurrence-free survival rate of 93%.
Area of Science:
- Urology
- Surgical Oncology
- Minimally Invasive Surgery
Background:
- Robotic postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) feasibility and safety are established for testicular cancer.
- Limited data exist on the long-term oncological outcomes of robotic PC-RPLND in testicular cancer patients.
Purpose of the Study:
- To evaluate the oncological outcomes of robotic PC-RPLND in patients with testicular cancer.
- To assess recurrence-free survival (RFS) and cancer control following robotic PC-RPLND.
Main Methods:
- Retrospective cohort study involving 173 testicular cancer patients undergoing robotic PC-RPLND across 11 academic centers (2011-2023).
- Analysis of patient characteristics, clinicopathological findings, and oncological outcomes.
- Recurrence-free survival estimated using the Kaplan-Meier method.
Main Results:
- The 4-year recurrence-free survival rate was 93%, with only 8 recurrences observed at a median follow-up of 22 months.
- Pure robotic PC-RPLND (159 patients) demonstrated favorable outcomes, with viable germ-cell tumor in 11% of cases.
- Conversion to open surgery (14 patients) was associated with higher complication rates but similar oncological outcomes.
Conclusions:
- Robotic PC-RPLND provides acceptable intermediate-term oncological outcomes for appropriately selected testicular cancer patients.
- The procedure demonstrates effective cancer control, supporting its role in managing advanced testicular cancer.
